Prurigo nodularis: Hautmikrobiom verdeutlicht pathophysiologische Verwandtschaft mit atopischer Dermatitis
Published in Kompass Dermatologie
Published in Kompass Dermatologie
Published in Kompass Dermatologie
Background: Prurigo nodularis is a chronic skin disease characterised by intensely pruritic, hyperkeratotic nodules. Vixarelimab, a human monoclonal antibody, binds to the beta subunit of the oncostatin M receptor, inhibiting signalling of both interleukin 31 and oncostatin M, two cytokine pathways that contribute to pruritus and nodule formation i...
Published in Kompass Dermatologie
Background: Selective photothermolysis on sebaceous glands is an effective method for treating acne vulgaris (AV); however, safety, efficacy, and discomfort hinder its utilization in clinical settings. Aims: The primary objective is to evaluate the safety and efficacy of a novel 1726 nm laser with contact cooling to treat AV. Methods: Seventeen pat...
Published in Kompass Dermatologie
Die chronische noduläre Prurigo (CNPG) ist eine chronische, rezidivierende Juckreizkrankheit, die die Lebensqualität beeinträchtigt. Sie kann durch eine Vielzahl von Ursachen ausgelöst werden, darunter atopische Dermatitis, Diabetes und chronische Nierenerkrankungen. Die Mechanismen der CNPG sind komplex und beinhalten das Zusammenspiel von Haut-, ...
Published in Kompass Dermatologie
Published in Kompass Dermatologie
Background: Patients with prurigo nodularis (PN) have multiple itchy nodules, impaired quality of life and sleep deprivation. Prurigo nodularis patients have a high burden of disease, primarily due to the intensity of the itch. It is reasonable to expect that rapid relief of itch – and associated improvement of sleep – are highly valued clinical ou...
Published in Kompass Dermatologie
Prurigo nodularis (PN) is a chronic inflammatory skin disease with intensely pruritic nodules. The LIBERTY-PN PRIME and PRIME2 phase 3 trials enrolled adults with PN with ≥20 nodules and severe itch uncontrolled with topical therapies. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin (IL)-4 and IL-1...
Published in Kompass Dermatologie
Published in Kompass Dermatologie
Objective: To date, conflicting evidence has been reported regarding the energy settings to use during endovenous laser ablation (EVLA). In the present study, we evaluated the outcomes of EVLA of the great saphenous veins (GSVs) using different power settings with the same linear endovenous energy density (LEED) of ∼70 J/cm. Methods: We performed a...
Published in Kompass Dermatologie